Millions of fully vaccinated Americans will now be able to take an extra Covid-19 vaccine dose — but eligibility depends on the vaccine.
More than 75% of eligible Americans are at least partially vaccinated against Covid-19, but some health experts are concerned the vaccines — which are still highly effective at stemming hospitalizations and death — could wane in effectiveness for certain patients. As a result, the federal government and drugmakers have prepared to deliver booster shots to already-vaccinated people.
6 million Americans have taken booster shots, according toBy endorsing a mix-and-match approach to boosters, the CDC may cause some fully vaccinated people to look elsewhere for their extra dose.
Norge Siste Nytt, Norge Overskrifter
Similar News:Du kan også lese nyheter som ligner på denne som vi har samlet inn fra andre nyhetskilder.
Pfizer, BioNTech report high efficacy of COVID-19 booster shot in studyPfizer Inc and German partner BioNTech SE on Thursday said data from a Phase III trial demonstrated high efficacy of a booster dose of their COVID-19 vaccine against the virus, including the Delta variant.
Les mer »
Pfizer Says Its Booster Shot Shows 95.6% Efficacy Against Covid-19I am a London-based reporter for Forbes covering breaking news. Previously, I have worked as a reporter for a specialist legal publication covering big data and as a freelance journalist and policy analyst covering science, tech and health. I have a master’s degree in Biological Natural Sciences and a master’s degree in the History and Philosophy of Science from the University of Cambridge. Follow me on Twitter theroberthart or email me at rhartforbes.com
Les mer »
Pfizer-BioNTech Covid-19 Booster Shot Was 95.6% Effective in Large Trial, Companies SayThe study was carried out while the highly contagious Delta variant was prevalent, the companies said, suggesting the booster helps protect against the contagious strain.
Les mer »
Pfizer booster has 95.6% efficacy against COVID, large study showsA booster shot of the Pfizer-BioNTech vaccine is 95.6% effective against the coronavirus, compared with those who only had the first two initial doses, according to a large study released Thursday.Why it matters: The study, which had more than 10,000 participants aged 16 and older, is the first controlled, randomized trial looking at boosters and their effectiveness, the companies said.Get market news worthy of your time with Axios Markets. Subscribe for free.The companies said the study was con
Les mer »
EU regulator verdict on Moderna COVID-19 booster shot next weekThe European Union's drug regulator expects to announce the results of its review of Moderna's COVID-19 booster vaccine next week and also to start a rolling review of Merck's antiviral oral pill, a senior official said on Thursday.
Les mer »
CDC panel backs expanded rollout of COVID-19 boostersMillions more Americans are closer to getting a COVID-19 booster as influential government advisers on Thursday endorsed extra doses of all three of the...
Les mer »